Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin.
Rauch
Andri
A
Egger
Martin
M
Reichen
Jürg
J
Furrer
Hansjakob
H
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D004608:Eligibility Determination; D005260:Female; D015658:HIV Infections / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin